PHARMACEUTICAL DEVELOPMENT OF TAMOXIFEN CITRATE LOADED TRANSFEROSOMAL GEL FOR SKIN CANCER BY DOE APPROACH

Abstract

Objective: The purpose of the present study is to evaluate the transfersomal gel formulation for transdermal delivery of Tamoxifen citrate by DOE Approach.

Materials and Methods: Transferosomes are ultra-flexible supra-molecular aggregates with a great ability to permeate intact mammalian skin.The formulation were designed by Box-Behnkenn Design. For usage as a transferosomal gel, drug encapsulation in various transfersomal formulations having various ratios of different drug concentrations (0.05, 0.1, 0.2, 0.3, 0.4, 0.5 g) and Carbopol-940-934 (0.5,1.2 g) is being studied.

Results: Entrapment efficiency (EE percent), drug content, in-vitro skin penetration testing, and stability studies were all found in the produced formulations. Transmission Electron Microscopy confirmed that the vesicles were spherical in shape. According to the findings, tamoxifen citrate was effectively pinned with a standardised drug concentration in all formulations. The 0.1 g Tamoxifen citrate optimised transferosome formulation MG2 exhibited encouraging results, with maximum drug release (94.32%) and maximum drug release (94.32%), respectively (94.32%).

Conclusion: Transferosomes, according to this study, are a promising long-term delivery route for Tamoxifen citrate and are relatively stable. This research reveals that transferosomes containing Tamoxifen citrate could be used to treat squamous cell carcinoma via transdermal drug delivery.